1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Regulation

Study Progress Updated To ‘Ongoing’: FDA Publishes Interim Report Three Years Into Essure Study

 
• By Hannah Daniel

In a report on Bayer’s postmarket study of Essure, the FDA says Bayer’s study is back on track with its five-year plan.

• Source: Shutterstock

Bayer’s postmarket study of Essure is back on track after a sharp drop in participants in October 2022, the US Food and Drug Administration said in a three-year interim update.

Essure, a sterilization implant marketed by Bayer, was recalled in 2018 in the US. By the end of 2019, all...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

Case Study: Pushing The EU’s IVD Regulation To Its Limits With Next Generation Sequencing

 
• By Amanda Maxwell

Partnership, positive communication and passion were all key in establishing a regulatory route for groundbreaking genetic testing technology for hereditary diseases. So said Fulgent Genetics’ executives interviewed by MTI about their technology’s development pathway.

EU Begins To Define Secondary Uses Of Health Data Under EHDS

 
• By Amanda Maxwell

The medtech industry, eagerly awaiting clear guidance on how healthcare data can be shared and help drive innovation, can have its say.

Should the EU Allow eIFU For Some Lay Devices?

 
• By Amanda Maxwell

Electronic instructions for use are becoming increasingly prevalent in the medtech world, but so far in the EU do not extend to non-professional users.

OIG Urges Reforms To Medicare Skin Substitute Payments

Expect fresh scrutiny on skin substitute payments as the Office of the Inspector General found Medicare reimbursement for the products has continued its rapid increase despite fraud and abuse concerns.

More from Policy & Regulation

Biolinq Aims To ‘Shine’ In Early 2026 With Needle-Free CGM US Debut, Human Data On Protein Sensor

 
• By Marion Webb

Fresh off de novo clearance, Biolinq plans to launch its needle-free CGM for type 2 diabetes not on insulin in early 2026. Pricing has not been disclosed, but “won’t be too far apart” over rivals Abbott’s Lingo and Dexcom’s Stelo CGMs, CEO Rich Yang said.

Blood Volume, Reimagined: Daxor’s BVA Could Slash Testing Time and Save Lives

 
• By Elizabeth Orr

The Daxor Blood Volume Analysis (BVA) is aimed at improving care for heart failure patients. It will allow blood volume to be measured from the patient’s bedside for the first time and is also significantly faster than earlier testing methods.

FDA Wants Help In Figuring Out How AI-Enabled Devices Work In ‘The Real World’

 
• By Brian Bossetta

The US FDA is seeking public input on practical approaches to evaluating the performance of AI-enabled medical devices. The agency says it wants to build off insights gained from a public advisory committee last year that discussed how best to evaluate these devices once they are in use.